{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T11:14:24Z","timestamp":1758280464908},"reference-count":81,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2007,12,8]],"date-time":"2007-12-08T00:00:00Z","timestamp":1197072000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int Urol Nephrol"],"published-print":{"date-parts":[[2008,3]]},"DOI":"10.1007\/s11255-007-9307-6","type":"journal-article","created":{"date-parts":[[2007,12,7]],"date-time":"2007-12-07T13:57:35Z","timestamp":1197035855000},"page":"165-170","source":"Crossref","is-referenced-by-count":13,"title":["Statin therapy in peritoneal dialysis patients: effects beyond lipid lowering"],"prefix":"10.1007","volume":"40","author":[{"given":"Kosmas I.","family":"Paraskevas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2007,12,8]]},"reference":[{"key":"9307_CR1","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s11255-006-9064-y","volume":"39","author":"M Ahmad","year":"2007","unstructured":"Ahmad M, Shah H, Pliakogiannis T et\u00a0al (2007) Prevention of membrane damage in patient on peritoneal dialysis with new peritoneal dialysis solutions. Int Urol Nephrol 39:299\u2013312","journal-title":"Int Urol Nephrol"},{"key":"9307_CR2","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1093\/ndt\/gfl010","volume":"21","author":"H Jonge de","year":"2006","unstructured":"de Jonge H, Bammens B, Lemahieu W et\u00a0al (2006) Comparison of peritoneal dialysis and haemodialysis after renal transplant failure. Nephrol Dial Transplant 21:1669\u20131674","journal-title":"Nephrol Dial Transplant"},{"key":"9307_CR3","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s11255-006-0080-8","volume":"38","author":"T Soleymanian","year":"2006","unstructured":"Soleymanian T, Raman S, Shannaq FN et al (2006) Survival and morbidity of HIV patients on hemodialysis and peritoneal dialysis: one center\u2019s experience and review of the literature. Int Urol Nephrol 38:331\u2013338","journal-title":"Int Urol Nephrol"},{"key":"9307_CR4","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1007\/s11255-006-9160-z","volume":"39","author":"M Ahmad","year":"2007","unstructured":"Ahmad M (2007) Continuous ambulatory peritoneal dialysis in patients with renal failure due to multiple myeloma. Int Urol Nephrol 39:629\u2013633","journal-title":"Int Urol Nephrol"},{"issue":"4","key":"9307_CR5","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1007\/s11255-007-9279-6","volume":"39","author":"X Yang","year":"2007","unstructured":"Yang X, Fang W, Kothari J et\u00a0al (2007) Clinical outcomes of elderly patients undergoing chronic peritoneal dialysis: experiences from one center and a review of the literature. Int Urol Nephrol 39(4):1295\u20131302","journal-title":"Int Urol Nephrol"},{"key":"9307_CR6","doi-asserted-by":"crossref","first-page":"S280","DOI":"10.1177\/089686080102103S49","volume":"21","author":"SJ Davies","year":"2001","unstructured":"Davies SJ (2001) Peritoneal dialysis in the patient with a failing renal allograft. Perit Dial Int 21:S280\u2013S284","journal-title":"Perit Dial Int"},{"key":"9307_CR7","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s11255-006-9141-2","volume":"39","author":"T Salonen","year":"2007","unstructured":"Salonen T, Reina T, Oksa H et\u00a0al (2007) Alternative strategies to evaluate the cost-effectiveness of peritoneal dialysis and hemodialysis. Int Urol Nephrol 39:289\u2013298","journal-title":"Int Urol Nephrol"},{"key":"9307_CR8","first-page":"210","volume":"136","author":"JB Wasserfallen","year":"2006","unstructured":"Wasserfallen JB, Moinat M, Halabi G et\u00a0al (2006) Satisfaction of patients on chronic haemodialysis and peritoneal dialysis. Swiss Med Wkly 136:210\u2013217","journal-title":"Swiss Med Wkly"},{"key":"9307_CR9","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1007\/s11255-007-9225-7","volume":"39","author":"T Apostolou","year":"2007","unstructured":"Apostolou T (2007) Quality of life in the elderly patients on dialysis. Int Urol Nephrol 39:679\u2013683","journal-title":"Int Urol Nephrol"},{"key":"9307_CR10","doi-asserted-by":"crossref","first-page":"S300","DOI":"10.1177\/089686080102103S53","volume":"21","author":"JB Trbojevic","year":"2001","unstructured":"Trbojevic JB, Nesic VB, Stojimirovic BB (2001) Quality of life of elderly patients undergoing continuous ambulatory peritoneal dialysis. Peri Dial Int 21:S300\u2013S303","journal-title":"Peri Dial Int"},{"key":"9307_CR11","first-page":"137","volume":"20","author":"A Horinek","year":"2004","unstructured":"Horinek A, Misra M (2004) Does residual renal function decline more rapidly in hemodialysis than in peritoneal dialysis? How good is the evidence? Adv Perit Dial 20:137\u2013140","journal-title":"Adv Perit Dial"},{"key":"9307_CR12","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1111\/j.0894-0959.2004.17306.x","volume":"17","author":"SM Chandna","year":"2004","unstructured":"Chandna SM, Farrington K (2004) Residual renal function: considerations on its importance and preservation in dialysis patients. Semin Dial 17:196\u2013201","journal-title":"Semin Dial"},{"key":"9307_CR13","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1159\/000093520","volume":"150","author":"B Piraino","year":"2006","unstructured":"Piraino B (2006) Peritoneal dialysis infections recommendations. Contrib Nephrol 150:181\u2013186","journal-title":"Contrib Nephrol"},{"key":"9307_CR14","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s11255-004-1562-1","volume":"37","author":"E Thodis","year":"2005","unstructured":"Thodis E, Passadakis P, Lyrantzopoulos N et\u00a0al (2005) Peritoneal catheters and related infections. Int Urol Nephrol 37:379\u2013393","journal-title":"Int Urol Nephrol"},{"key":"9307_CR15","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1007\/s11255-007-9200-3","volume":"39","author":"SL Lui","year":"2007","unstructured":"Lui SL, Yip T, Tse KC et\u00a0al (2007) Tuberculous lymphadenitis in patients undergoing continuous ambulatory peritoneal dialysis. Int Urol Nephrol 39:971\u2013974","journal-title":"Int Urol Nephrol"},{"key":"9307_CR16","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1177\/039139880602900103","volume":"29","author":"C Bonifati","year":"2006","unstructured":"Bonifati C, Pansini F, Tones DD et\u00a0al (2006) Antimicrobial agents and catheter-related interventions to prevent peritonitis in peritoneal dialysis: using evidence in the context of clinical practice. Int J Artif Organs 29:41\u201349","journal-title":"Int J Artif Organs"},{"key":"9307_CR17","doi-asserted-by":"crossref","first-page":"S44","DOI":"10.1038\/sj.ki.5001915","volume":"103","author":"FH Bender","year":"2006","unstructured":"Bender FH, Bernardini J, Piraino B (2006) Prevention of infectious complications in peritoneal dialysis: best demonstrated practices. Kidney Int Suppl 103:S44\u2013S54","journal-title":"Kidney Int Suppl"},{"issue":"6 Suppl 5","key":"9307_CR18","first-page":"1","volume":"42","author":"[No authors listed]","year":"2003","unstructured":"[No authors listed] (2003) USRDS: the United States Renal Data System. Am J Kidney Dis 42(6 Suppl 5):1\u2013230","journal-title":"Am J Kidney Dis"},{"key":"9307_CR19","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1038\/ncpneph0447","volume":"3","author":"R Katneni","year":"2007","unstructured":"Katneni R, Hedayati SS (2007) Central venous catheter-related bacteremia in chronic hemodialysis patients: epidemiology and evidence-based management. Nat Clin Pract Nephrol 3:256\u2013266","journal-title":"Nat Clin Pract Nephrol"},{"key":"9307_CR20","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1053\/j.ackd.2006.04.009","volume":"13","author":"CE Lok","year":"2006","unstructured":"Lok CE (2006) Avoiding trouble down the line: the management and prevention of hemodialysis catheter-related infections. Adv Chronic Kidney Dis 13:225\u2013244","journal-title":"Adv Chronic Kidney Dis"},{"key":"9307_CR21","doi-asserted-by":"crossref","first-page":"309","DOI":"10.2174\/1570161043385475","volume":"2","author":"A Yildirir","year":"2004","unstructured":"Yildirir A, M\u00fcderrisoglu H (2004) Non-lipid effects of statins: emerging new indications. Curr Vasc Pharmacol 2:309\u2013318","journal-title":"Curr Vasc Pharmacol"},{"key":"9307_CR22","doi-asserted-by":"crossref","first-page":"942","DOI":"10.2174\/138945007781386893","volume":"8","author":"KI Paraskevas","year":"2007","unstructured":"Paraskevas KI, Athyros VG, Briana DD et\u00a0al (2007) Statins exert multiple beneficial effects on patients undergoing percutaneous revascularization procedures. Curr Drug Targets 8:942\u2013951","journal-title":"Curr Drug Targets"},{"key":"9307_CR23","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1097\/01.hco.0000181482.99067.bf","volume":"20","author":"P Calabr\u00f2","year":"2005","unstructured":"Calabr\u00f2 P, Yeh ET (2005) The pleiotropic effects of statins. Curr Opin Cardiol 20:541\u2013546","journal-title":"Curr Opin Cardiol"},{"key":"9307_CR24","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/3-540-27661-0_13","volume":"170","author":"R Paoletti","year":"2005","unstructured":"Paoletti R, Bolego C, Cignarella A (2005) Lipid and non-lipid effects of statins. Handb Exp Pharmacol 170:365\u2013388","journal-title":"Handb Exp Pharmacol"},{"key":"9307_CR25","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.jvs.2007.03.035","volume":"46","author":"KI Paraskevas","year":"2007","unstructured":"Paraskevas KI, Hamilton G, Mikhailidis DP (2007) Statins: an essential component in the management of carotid artery disease. J Vasc Surg 46:373\u2013386","journal-title":"J Vasc Surg"},{"key":"9307_CR26","first-page":"CD004289","volume":"4","author":"SD Navaneethan","year":"2004","unstructured":"Navaneethan SD, Shrivastava R (2004) HMG CoA reductase inhibitors (statins) for dialysis patients. Cochrane Database Syst Rev 4:CD004289","journal-title":"Cochrane Database Syst Rev"},{"key":"9307_CR27","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1007\/s11255-006-9162-x","volume":"39","author":"H Abo-Zenah","year":"2007","unstructured":"Abo-Zenah H, Sabry A, Farouk A et\u00a0al (2007) The impact of haemodialysis-associated variables on lipid profile in Egyptian haemodialysis population. Int Urol Nephrol 39:609\u2013618","journal-title":"Int Urol Nephrol"},{"key":"9307_CR28","doi-asserted-by":"crossref","first-page":"299","DOI":"10.5414\/CNP61299","volume":"61","author":"CS Fox","year":"2004","unstructured":"Fox CS, Longenecker JC, Powe NR et\u00a0al (2004) Undertreatment of hyperlipidemia in a cohort of United States kidney dialysis patients. Clin Nephrol 61:299\u2013307","journal-title":"Clin Nephrol"},{"key":"9307_CR29","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.2215\/CJN.00780306","volume":"1","author":"ME Molitch","year":"2006","unstructured":"Molitch ME (2006) Management of dyslipidemias in patients with diabetes and chronic kidney disease. Clin J Am Soc Nephrol 1:1090\u20131099","journal-title":"Clin J Am Soc Nephrol"},{"key":"9307_CR30","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1038\/ki.1992.204","volume":"41","author":"M Senti","year":"1992","unstructured":"Senti M, Romero R, Pedro-Botet J et\u00a0al (1992) Lipoprotein abnormalities in hyperlipidemic and normolipidemic men on hemodialysis with chronic renal failure. Kidney Int 41:1394\u20131399","journal-title":"Kidney Int"},{"key":"9307_CR31","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S0272-6386(12)70318-9","volume":"22","author":"AK Cheung","year":"1993","unstructured":"Cheung AK, Wu LL, Kablitz C et\u00a0al (1993) Atherogenic lipids and lipoproteins in hemodialysis patients. Am J Kidney Dis 22:271\u2013276","journal-title":"Am J Kidney Dis"},{"key":"9307_CR32","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1161\/01.CIR.86.2.475","volume":"86","author":"MD Cressman","year":"1992","unstructured":"Cressman MD, Heyka RJ, Paganini EP et\u00a0al (1992) Lipoprotein(a) is an independent risk factor for cardiovascular disease in hemodialysis patients. Circulation 86:475\u2013482","journal-title":"Circulation"},{"key":"9307_CR33","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1681\/ASN.V61110","volume":"6","author":"F Kronenberg","year":"1995","unstructured":"Kronenberg F, K\u00f6nig P, Neyer U et\u00a0al (1995) Multicenter study of lipoprotein(a) and apolipoprotein(a) phenotypes in patients with end-stage renal disease treated by hemodialysis or continuous ambulatory peritoneal dialysis. J Am Soc Nephrol 6:110\u2013120","journal-title":"J Am Soc Nephrol"},{"key":"9307_CR34","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1177\/089686089501500410","volume":"15","author":"KC Siamopoulos","year":"1995","unstructured":"Siamopoulos KC, Elisaf MS, Bairaktari HT et\u00a0al (1995) Lipid parameters including lipoprotein (a) in patients undergoing CAPD and hemodialysis. Perit Dial Int 15:342\u2013347","journal-title":"Perit Dial Int"},{"key":"9307_CR35","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/ki.1991.22","volume":"39","author":"G Appel","year":"1991","unstructured":"Appel G (1991) Lipid abnormalities in renal disease. Kidney Int 39:169\u2013183","journal-title":"Kidney Int"},{"key":"9307_CR36","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1111\/j.1525-1594.1995.tb02321.x","volume":"19","author":"ME Canziani","year":"1995","unstructured":"Canziani ME, Cendoroglo Neto M, Saragoca MA et\u00a0al (1995) Hemodialysis versus continuous ambulatory peritoneal dialysis: effects on the heart. Artif Organs 19:241\u2013244","journal-title":"Artif Organs"},{"key":"9307_CR37","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2164-4-1","volume":"4","author":"KC Abbott","year":"2003","unstructured":"Abbott KC, Trespalacios FC, Taylor AJ et\u00a0al (2003) Atrial fibrillation in chronic dialysis patients in the United States: risk factors for hospitalization and mortality. BMC 4:1","journal-title":"BMC"},{"key":"9307_CR38","first-page":"S4","volume":"40","author":"R Maiorca","year":"1993","unstructured":"Maiorca R, Cancarini GC, Brunori G et\u00a0al (1993) Morbidity and mortality of CAPD and hemodialysis. Kidney Int Suppl 40:S4\u2013S15","journal-title":"Kidney Int Suppl"},{"key":"9307_CR39","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1093\/ndt\/15.5.684","volume":"15","author":"G Hufnagel","year":"2000","unstructured":"Hufnagel G, Michel C, Vrtovsnik F et\u00a0al (2000) Effects of atorvastatin on dyslipidaemia in uraemic patients on peritoneal dialysis. Nephrol Dial Transplant 15:684\u2013688","journal-title":"Nephrol Dial Transplant"},{"key":"9307_CR40","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s10157-006-0425-8","volume":"10","author":"D Saltissi","year":"2006","unstructured":"Saltissi D, Westhuyzen J, Morgan C et\u00a0al (2006) Efficacy, safety and tolerability of atorvastatin in dyslipidemic subjects with advanced (non-nephrotic) and endstage chronic renal failure. Clin Exp Nephrol 10:201\u2013209","journal-title":"Clin Exp Nephrol"},{"key":"9307_CR41","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1046\/j.1523-1755.2002.00262.x","volume":"61","author":"KP Harris","year":"2002","unstructured":"Harris KP, Wheeler DC, Chong CC (2002) A placebo-controlled trial examining atorvastatin in dyslipidemic patients undergoing CAPD. Kidney Int 61:1469\u20131474","journal-title":"Kidney Int"},{"key":"9307_CR42","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.1681\/ASN.V92267","volume":"9","author":"RN Foley","year":"1998","unstructured":"Foley RN, Parfrey PS, Sarnak MJ (1998) Epidemiology of cardiovascular disease in chronic renal disease. J Am Soc Nephrol 9:S16\u2013S23","journal-title":"J Am Soc Nephrol"},{"key":"9307_CR43","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/s11255-006-9032-6","volume":"39","author":"S Maitra","year":"2007","unstructured":"Maitra S, Sekercioglu N, Baloch S et\u00a0al (2007) Causes of death in older peritoneal dialysis patients\u2014can we depend on registry reports? Int Urol Nephrol 39:345\u2013350","journal-title":"Int Urol Nephrol"},{"key":"9307_CR44","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1007\/s11255-006-0039-9","volume":"38","author":"LP Soubassi","year":"2006","unstructured":"Soubassi LP, Chiras TC, Papadakis ED et\u00a0al (2006) Incidence and risk factors of coronary heart disease in elderly patients on chronic hemodialysis. Int Urol Nephrol 38:795\u2013800","journal-title":"Int Urol Nephrol"},{"key":"9307_CR45","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1097\/01.ASN.0000069165.79509.42","volume":"14","author":"P Stenvinkel","year":"2003","unstructured":"Stenvinkel P, Pecoits-Filho R, Lindholm B (2003) Coronary artery disease in end-stage renal disease: no longer a simple plumbing problem. J Am Soc Nephrol 14:1927\u20131939","journal-title":"J Am Soc Nephrol"},{"key":"9307_CR46","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1056\/NEJMoa021993","volume":"347","author":"PM Ridker","year":"2002","unstructured":"Ridker PM, Rifai N, Rose L et\u00a0al (2002) Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 347:1557\u20131565","journal-title":"N Engl J Med"},{"key":"9307_CR47","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1681\/ASN.V124814","volume":"12","author":"KA Herzig","year":"2001","unstructured":"Herzig KA, Purdie DM, Chang W et\u00a0al (2001) Is C-reactive protein a useful predictor of outcome in peritoneal dialysis patients? J Am Soc Nephrol 12:814\u2013821","journal-title":"J Am Soc Nephrol"},{"key":"9307_CR48","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1093\/ndt\/14.8.1956","volume":"14","author":"K Iseki","year":"1999","unstructured":"Iseki K, Tozawa M, Yoshi S et\u00a0al (1999) Serum C-reactive protein (CRP) and risk of death in chronic dialysis patients. Nephrol Dial Transplant 14:1956\u20131960","journal-title":"Nephrol Dial Transplant"},{"key":"9307_CR49","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1007\/s11255-007-9226-6","volume":"39","author":"M Wei","year":"2007","unstructured":"Wei M, Bargman JM, Oreopoulos DG (2007) Factors related to erythropoietin hypo-responsiveness in patients on chronic peritoneal dialysis. Int Urol Nephrol 39:935\u2013940","journal-title":"Int Urol Nephrol"},{"key":"9307_CR50","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1592\/phco.2005.25.10.1365","volume":"25","author":"KM Field","year":"2005","unstructured":"Field KM (2005) Effect of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on high-sensitivity C-reactive protein levels. Pharmacotherapy 25:1365\u20131377","journal-title":"Pharmacotherapy"},{"key":"9307_CR51","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/j.1527-3466.2006.00033.x","volume":"24","author":"K Prasad","year":"2006","unstructured":"Prasad K (2006) C-reactive protein (CRP)-lowering agents. Cardiovasc Drug Rev 24:33\u201350","journal-title":"Cardiovasc Drug Rev"},{"key":"9307_CR52","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/S0002-9149(00)01516-2","volume":"87","author":"T Holm","year":"2001","unstructured":"Holm T, Andreassen AK, Ueland T et\u00a0al (2001) Effect of pravastatin on plasma markers of inflammation and peripheral endothelial function in male heart transplant recipients. Am J Cardiol 87:815\u2013818","journal-title":"Am J Cardiol"},{"key":"9307_CR53","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1159\/000085525","volume":"149","author":"P Stenvinkel","year":"2005","unstructured":"Stenvinkel P (2005) Inflammation in end-stage renal disease\u2014a fire that burns within. Contrib Nephrol 149:185\u2013199","journal-title":"Contrib Nephrol"},{"key":"9307_CR54","doi-asserted-by":"crossref","first-page":"281","DOI":"10.2215\/CJN.01281005","volume":"1","author":"P Stenvinkel","year":"2006","unstructured":"Stenvinkel P, Rodr\u00edguez-Ayala E, Massy ZA et\u00a0al (2006) Statin treatment and diabetes affect myeloperoxidase activity in maintenance hemodialysis patients. Clin J Am Soc Nephrol 1:281\u2013287","journal-title":"Clin J Am Soc Nephrol"},{"key":"9307_CR55","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1093\/ndt\/gfi224","volume":"21","author":"V Panichi","year":"2006","unstructured":"Panichi V, Paoletti S, Mantuano E et\u00a0al (2006) In\u00a0vivo and in\u00a0vitro effects of simvastatin on inflammatory markers in pre-dialysis patients. Nephrol Dial Transplant 21:337\u2013344","journal-title":"Nephrol Dial Transplant"},{"key":"9307_CR56","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.biopha.2007.03.002","volume":"61","author":"E Mantuano","year":"2007","unstructured":"Mantuano E, Santi S, Filippi C et\u00a0al (2007) Simvastatin and fluvastatin reduce interleukin-6 and interleukin-8 lipopolysaccharide (LPS) stimulated production by isolated human monocytes from chronic kidney disease patients. Biomed Pharmacother 61:360\u2013365","journal-title":"Biomed Pharmacother"},{"key":"9307_CR57","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1159\/000082166","volume":"22","author":"G Tsirpanlis","year":"2004","unstructured":"Tsirpanlis G, Boufidou F, Manganas S et\u00a0al (2004) Treatment with fluvastatin rapidly modulates, via different pathways, and in dependence on the baseline level, inflammation in hemodialysis patients. Blood Purif 22:518\u2013524","journal-title":"Blood Purif"},{"key":"9307_CR58","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1046\/j.1523-1755.2002.00109.x","volume":"61","author":"SL Seliger","year":"2002","unstructured":"Seliger SL, Weiss NS, Gillen DL et\u00a0al (2002) HMG-CoA reductase inhibitors are associated with reduced mortality in ESRD patients. Kidney Int 61:297\u2013304","journal-title":"Kidney Int"},{"key":"9307_CR59","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1053\/j.ajkd.2004.09.025","volume":"45","author":"NA Mason","year":"2005","unstructured":"Mason NA, Bailie GR, Satayathum S et\u00a0al (2005) HMG-coenzyme a reductase inhibitor use is associated with mortality reduction in hemodialysis patients. Am J Kidney Dis 45:119\u2013126","journal-title":"Am J Kidney Dis"},{"key":"9307_CR60","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1056\/NEJMoa043545","volume":"353","author":"C Wanner","year":"2005","unstructured":"Wanner C, Krane V, M\u00e4rz W et\u00a0al (2005) Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 353:238\u2013248","journal-title":"N Engl J Med"},{"key":"9307_CR61","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMoa050461","volume":"352","author":"JC LaRosa","year":"2005","unstructured":"LaRosa JC, Grundy SM, Waters DD et al (2005) Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 352:1425\u20131435","journal-title":"N Engl J Med"},{"key":"9307_CR62","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1016\/j.jacc.2006.07.041","volume":"48","author":"DD Waters","year":"2006","unstructured":"Waters DD, LaRosa JC, Barter P et\u00a0al (2006) Effects of high-dose atorvastatin on cerebrovascular events in patients with stable coronary disease in the TNT (treating to new targets) study. J Am Coll Cardiol 48:1793\u20131799","journal-title":"J Am Coll Cardiol"},{"key":"9307_CR63","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1159\/000106803","volume":"30","author":"B Fellstr\u00f6m","year":"2007","unstructured":"Fellstr\u00f6m B, Holdaas H, Jardine AG et\u00a0al (2007) Effect of rosuvastatin on outcomes in chronic haemodialysis patients: baseline data from the AURORA study. Kidney Blood Press Res 30:314\u2013322","journal-title":"Kidney Blood Press Res"},{"key":"9307_CR64","doi-asserted-by":"crossref","first-page":"S207","DOI":"10.1046\/j.1523-1755.63.s84.4.x","volume":"84","author":"C Baigent","year":"2003","unstructured":"Baigent C, Landry M (2003) Study of Heart and Renal Protection (SHARP). Kidney Int Suppl 84:S207\u2013S210","journal-title":"Kidney Int Suppl"},{"key":"9307_CR65","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1038\/sj.ki.5002174","volume":"71","author":"VM Campese","year":"2007","unstructured":"Campese VM, Park J (2007) HMG-CoA reductase inhibitors and the kidney. Kidney Int 71:1215\u20131222","journal-title":"Kidney Int"},{"issue":"4 Suppl 2","key":"9307_CR66","doi-asserted-by":"crossref","first-page":"S148","DOI":"10.1681\/ASN.2005121341","volume":"17","author":"G D\u2019Amico","year":"2006","unstructured":"D\u2019Amico G (2006) Statins and renal diseases: from primary prevention to renal replacement therapy. J Am Soc Nephrol 17(4 Suppl 2):S148\u2013S152","journal-title":"J Am Soc Nephrol"},{"key":"9307_CR67","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1016\/j.amjcard.2005.12.052","volume":"97","author":"DG Vidt","year":"2006","unstructured":"Vidt DG, Harris S, McTaggart F et\u00a0al (2006) Effect of short-term rosuvastatin treatment on estimated glomerular filtration rate. Am J Cardiol 97:1602\u20131606","journal-title":"Am J Cardiol"},{"key":"9307_CR68","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1053\/j.ackd.2005.01.007","volume":"12","author":"S Shah","year":"2005","unstructured":"Shah S, Paparello J, Danesh FR (2005) Effects of statin therapy on the progression of chronic kidney disease. Adv Chronic Kidney Dis 12:187\u2013195","journal-title":"Adv Chronic Kidney Dis"},{"key":"9307_CR69","doi-asserted-by":"crossref","first-page":"S152","DOI":"10.1111\/j.1523-1755.2005.09927.x","volume":"99","author":"F Locatelli","year":"2005","unstructured":"Locatelli F, Del Vecchio L, Pozzoni P (2005) Clinical benefits of slowing the progression of renal failure. Kidney Int Suppl 99:S152\u2013S156","journal-title":"Kidney Int Suppl"},{"key":"9307_CR70","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1046\/j.1523-1755.2002.00601.x","volume":"62","author":"B Haslinger","year":"2002","unstructured":"Haslinger B, Goedde MF, Toet KH et\u00a0al (2002) Simvastatin increases fibrinolytic activity in human peritoneal mesothelial cells independent of cholesterol lowering. Kidney Int 62:1611\u20131619","journal-title":"Kidney Int"},{"key":"9307_CR71","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1177\/089686089201200105","volume":"12","author":"JW Dobbie","year":"1992","unstructured":"Dobbie JW (1992) Pathogenesis of peritoneal fibrosing syndromes (sclerosing peritonitis) in peritoneal dialysis. Perit Dial Int 12:14\u201327","journal-title":"Perit Dial Int"},{"key":"9307_CR72","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1007\/s11255-007-9193-y","volume":"39","author":"L Lund","year":"2007","unstructured":"Lund L, J\u00f8nler M (2007) Peritoneal dialysis catheter placement: is laparoscopy an option? Int Urol Nephrol 39:625\u2013628","journal-title":"Int Urol Nephrol"},{"key":"9307_CR73","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1136\/bmj.326.7404.1423","volume":"326","author":"MR Law","year":"2003","unstructured":"Law MR, Wald NJ, Rudnicka AR (2003) Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ 326:1423\u20131427","journal-title":"BMJ"},{"key":"9307_CR74","doi-asserted-by":"crossref","first-page":"910","DOI":"10.7326\/0003-4819-142-11-200506070-00009","volume":"142","author":"NK Choudhry","year":"2005","unstructured":"Choudhry NK, Avorn J (2005) Over-the-counter statins. Ann Intern Med 142:910\u2013913","journal-title":"Ann Intern Med"},{"key":"9307_CR75","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1097\/00041552-200203000-00001","volume":"11","author":"DA Sica","year":"2002","unstructured":"Sica DA, Gehr TW (2002) 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and rhabdomyolysis: considerations in the renal failure patient. Curr Opin Nephrol Hypertens 11:123\u2013133","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"9307_CR76","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1002\/j.1552-4604.1997.tb05629.x","volume":"37","author":"RH Stern","year":"1997","unstructured":"Stern RH, Yang BB, Horton M et\u00a0al (1997) Renal dysfunction does not alter the pharmacokinetics or LDL-cholesterol reduction of atorvastatin. J Clin Pharmacol 37:816\u2013819","journal-title":"J Clin Pharmacol"},{"key":"9307_CR77","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1177\/00912700222011346","volume":"42","author":"S Appel-Dingemanse","year":"2002","unstructured":"Appel-Dingemanse S, Smith T, Merz M (2002) Pharmacokinetics of fluvastatin in subjects with renal impairment and nephrotic syndrome. J Clin Pharmacol 42:312\u2013318","journal-title":"J Clin Pharmacol"},{"key":"9307_CR78","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s002280050348","volume":"53","author":"TW Gehr","year":"1997","unstructured":"Gehr TW, Sica DA, Slugg PH et\u00a0al (1997) The pharmacokinetics of pravastatin in patients on chronic hemodialysis. Eur J Clin Pharmacol 53:117\u2013121","journal-title":"Eur J Clin Pharmacol"},{"key":"9307_CR79","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s002280100329","volume":"57","author":"M Igel","year":"2001","unstructured":"Igel M, Sudhop T, von Bergmann K (2001) Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A-reductase inhibitors (statins). Eur J Clin Pharmacol 57:357\u2013364","journal-title":"Eur J Clin Pharmacol"},{"key":"9307_CR80","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1080\/08860220701395002","volume":"29","author":"LH Gowdak","year":"2007","unstructured":"Gowdak LH, Arantes RL, de Paula FJ et\u00a0al (2007) Underuse of American College of Cardiology\/American Heart Association Guidelines in hemodialysis patients. Ren Fail 29:559\u2013565","journal-title":"Ren Fail"},{"key":"9307_CR81","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1046\/j.1525-139X.2003.16036.x","volume":"16","author":"SL Seliger","year":"2003","unstructured":"Seliger SL, Stehman-Breen CO (2003) Are HMG-CoA reductase inhibitors underutilized in dialysis patients? Semin Dial 16:179\u2013185","journal-title":"Semin Dial"}],"container-title":["International Urology and Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-007-9307-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11255-007-9307-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-007-9307-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,30]],"date-time":"2021-08-30T05:17:49Z","timestamp":1630300669000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11255-007-9307-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,12,8]]},"references-count":81,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2008,3]]}},"alternative-id":["9307"],"URL":"https:\/\/doi.org\/10.1007\/s11255-007-9307-6","relation":{},"ISSN":["0301-1623","1573-2584"],"issn-type":[{"value":"0301-1623","type":"print"},{"value":"1573-2584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,12,8]]}}}